Seeking Alpha

XenoPort soars off upbeat preliminary results from Phase I studies of its potential MS treatment

  • Shares of XenoPort (XNPT +18%) soar today after the company released positive preliminary results late yesterday from two Phase I studies of XP23829.
  • Based on the favorable results, XNPT intends to continue to advance development of the drug as a potential treatment for patients with relapsing-remitting multiple sclerosis and/or psoriasis.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)